ArticleBrain tumor research and treatment2025
Gamma Knife Radiosurgery for Advanced and Recurrent Juvenile Nasopharyngeal Angiofibroma: A Case Series.
Article in Brain tumor research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile nasopharyngeal angiofibroma (JNA) is a rare, benign, but locally aggressive tumor that typically affects adolescent males. While surgical resection is the standard treatment, achieving total resection is often challenging in advanced-stage tumors with intracranial extension, resulting in high recurrence rates. Gamma knife radiosurgery (GKRS) has been suggested as a potential adjuvant or salvage therapy, but evidence remains limited. In this study, we report three pediatric cases of advanced-stage JNA treated with GKRS following incomplete surgical resection. Two patients demonstrated durable local tumor control with a significant reduction in tumor size until 2 and 12 years after GKRS. The other patient with partial coverage of tumor by prescription isodose 12 Gy showed a reduction of tumor volume at 6 months but subsequent progression at 1 year. No GKRS-related complications were observed during the follow-up period. Our findings suggest that GKRS appears to be a potentially safe and effective treatment modality for residual or recurrent JNAs. Fractionated or staged GKRS combined with surgery may be a preferable strategy for large tumors in which extensive surgery alone, conventional radiotherapy, or single-fraction radiosurgery may be associated with increased morbidity in pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.